Treatment of IBD has changed considerably during recent years with more frequent use of classical immunomodulatory drugs such as azathoprine and the introduction of biologicals, that is, anti-TNF drugs.23 At the same time, the frequency of surgery for IBD has decreased and is reserved for the most severe cases.24 We speculate that the later appearance of uveitis in our IBD cohort and the overall low occurrence rate of intraocular inflammation could be a consequence of a widespread use of azathioprine and biologicals. The gene discussed is TNF; the disease is uveitis.